Literature DB >> 32790346

Glycan-Modified Virus-like Particles Evoke T Helper Type 1-like Immune Responses.

Mohammad Murshid Alam1, Cassie M Jarvis1, Robert Hincapie2, Craig S McKay2, Jiri Schimer2, Carlos A Sanhueza2, Ke Xu, Roger C Diehl1, M G Finn2, Laura L Kiessling1.   

Abstract

Dendritic cells (DCs) are highly effective antigen-presenting cells that shape immune responses. Vaccines that deliver antigen to the DCs can harness their power. DC surface lectins recognize glycans not typically present on host tissue to facilitate antigen uptake and presentation. Vaccines that target these surface lectins should offer improved antigen delivery, but their efficacy will depend on how lectin targeting influences the T cell subtypes that result. We examined how antigen structure influences uptake and signaling from the C-type lectin DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin or CD209). Virus-like particles (VLPs) were engineered from bacteriophage Qβ to present an array of mannoside ligands. The VLPs were taken up by DCs and efficiently trafficked to endosomes. The signaling that ensued depended on the ligand displayed on the VLP: only those particles densely functionalized with an aryl mannoside, Qβ-Man540, elicited DC maturation and induced the expression of the proinflammatory cytokines characteristic of a T helper type 1 (TH1)-like immune response. This effect was traced to differential binding to DC-SIGN at the acidic pH of the endosome. Mice immunized with a VLP bearing the aryl mannoside, and a peptide antigen (Qβ-Ova-Man540) had antigen-specific responses, including the production of CD4+ T cells producing the activating cytokines interferon-γ and tumor necrosis factor-α. A TH1 response is critical for intracellular pathogens (e.g., viruses) and cancer; thus, our data highlight the value of targeting DC lectins for antigen delivery and validate the utility of DC-targeted VLPs as vaccine vehicles that induce cellular immunity.

Entities:  

Keywords:  DC-SIGN; TH1-type immunity; bacteriophage Qβ; cytokines; dendritic cell; mannose; virus-like particles

Mesh:

Substances:

Year:  2020        PMID: 32790346      PMCID: PMC8249087          DOI: 10.1021/acsnano.0c03023

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  75 in total

1.  Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects.

Authors:  Tazio Storni; Christiane Ruedl; Katrin Schwarz; Reto A Schwendener; Wolfgang A Renner; Martin F Bachmann
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

2.  C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB.

Authors:  Sonja I Gringhuis; Jeroen den Dunnen; Manja Litjens; Bert van Het Hof; Yvette van Kooyk; Teunis B H Geijtenbeek
Journal:  Immunity       Date:  2007-04-26       Impact factor: 31.745

Review 3.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

4.  Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway.

Authors:  Stephanie J Win; Vernon K Ward; P Rod Dunbar; Sarah L Young; Margaret A Baird
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

5.  Multivalency as a chemical organization and action principle.

Authors:  Carlo Fasting; Christoph A Schalley; Marcus Weber; Oliver Seitz; Stefan Hecht; Beate Koksch; Jens Dernedde; Christina Graf; Ernst-Walter Knapp; Rainer Haag
Journal:  Angew Chem Int Ed Engl       Date:  2012-09-05       Impact factor: 15.336

6.  Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Authors:  Fernando Ulloa-Montoya; Jamila Louahed; Benjamin Dizier; Olivier Gruselle; Bart Spiessens; Frédéric F Lehmann; Stefan Suciu; Wim H J Kruit; Alexander M M Eggermont; Johan Vansteenkiste; Vincent G Brichard
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

7.  Molecular basis of the differences in binding properties of the highly related C-type lectins DC-SIGN and L-SIGN to Lewis X trisaccharide and Schistosoma mansoni egg antigens.

Authors:  Ellis Van Liempt; Anne Imberty; Christine M C Bank; Sandra J Van Vliet; Yvette Van Kooyk; Teunis B H Geijtenbeek; Irma Van Die
Journal:  J Biol Chem       Date:  2004-06-07       Impact factor: 5.157

8.  Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.

Authors:  Wendy Wj Unger; Christian T Mayer; Steef Engels; Christina Hesse; Maurizio Perdicchio; Franz Puttur; Ingeborg Streng-Ouwehand; Manja Litjens; Hakan Kalay; Luciana Berod; Tim Sparwasser; Yvette van Kooyk
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

9.  Escherichia coli-derived virus-like particles in vaccine development.

Authors:  Xiaofen Huang; Xin Wang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  NPJ Vaccines       Date:  2017-02-09       Impact factor: 7.344

10.  Single-cell RNA-seq reveals dynamic paracrine control of cellular variation.

Authors:  Alex K Shalek; Rahul Satija; Joe Shuga; John J Trombetta; Dave Gennert; Diana Lu; Peilin Chen; Rona S Gertner; Jellert T Gaublomme; Nir Yosef; Schraga Schwartz; Brian Fowler; Suzanne Weaver; Jing Wang; Xiaohui Wang; Ruihua Ding; Raktima Raychowdhury; Nir Friedman; Nir Hacohen; Hongkun Park; Andrew P May; Aviv Regev
Journal:  Nature       Date:  2014-06-11       Impact factor: 49.962

View more
  8 in total

Review 1.  Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines.

Authors:  Hunter McFall-Boegeman; Xuefei Huang
Journal:  Expert Rev Vaccines       Date:  2022-01-24       Impact factor: 5.217

Review 2.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

3.  Comprehensive Profiling Analysis of CD209 in Malignancies Reveals the Therapeutic Implication for Tumor Patients Infected With SARS-CoV-2.

Authors:  Jinyuan Li; Shuzhao Chen; Yang Li; Ziang Zhu; Hanying Huang; Weida Wang; Yao Yang; Yang Liang; Lingling Shu
Journal:  Front Genet       Date:  2022-06-17       Impact factor: 4.772

4.  Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy.

Authors:  Luya Cai; Xuedan Du; Cheng Zhang; Shanshan Yu; Lixiao Liu; Jinduo Zhao; Ye Zhao; Chunhong Zhang; Jinting Wu; Bin Wang; Yingyu Chen; Xiaoping Su; Xiaojian Yan; Wenfeng Li
Journal:  Cancer Immunol Immunother       Date:  2021-11-03       Impact factor: 6.630

5.  Synthetic Glyconanoparticles Modulate Innate Immunity but Not the Complement System.

Authors:  Chandradhish Ghosh; Patricia Priegue; Harin Leelayuwapan; Felix F Fuchsberger; Christoph Rademacher; Peter H Seeberger
Journal:  ACS Appl Bio Mater       Date:  2022-04-18

6.  Synthetic Glycomacromolecules of Defined Valency, Absolute Configuration, and Topology Distinguish between Human Lectins.

Authors:  Manuel Hartweg; Yivan Jiang; Gokhan Yilmaz; Cassie M Jarvis; Hung V-T Nguyen; Gastón A Primo; Alessandra Monaco; Valentin P Beyer; Kathleen K Chen; Somesh Mohapatra; Simon Axelrod; Rafael Gómez-Bombarelli; Laura L Kiessling; C Remzi Becer; Jeremiah A Johnson
Journal:  JACS Au       Date:  2021-08-10

7.  Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response.

Authors:  Qiong Long; Ying Yang; Mengli Yang; Hongmei Bai; Wenjia Sun; Xu Yang; Weiwei Huang; Duo Li; Yanbing Ma
Journal:  Nanomedicine       Date:  2022-01-30       Impact factor: 5.307

Review 8.  Immunobiology of Carbohydrates: Implications for Novel Vaccine and Adjuvant Design Against Infectious Diseases.

Authors:  Giuseppe Stefanetti; Francesco Borriello; Barbara Richichi; Ivan Zanoni; Luigi Lay
Journal:  Front Cell Infect Microbiol       Date:  2022-01-18       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.